Arbutus Biopharma
ABUS
ABUS
71 hedge funds and large institutions have $92.6M invested in Arbutus Biopharma in 2018 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 22 increasing their positions, 20 reducing their positions, and 25 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
71
Holders Change
-17
Holders Change %
-19.32%
% of All Funds
1.58%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
9
Increased
22
Reduced
20
Closed
25
Calls
$798K
Puts
$621K
Net Calls
+$177K
Net Calls Change
-$64K
Top Buyers
Top Sellers
1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$4.7M |
2 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$4.19M |
3 |
EI
EAM Investors
Solana Beach,
California
|
-$3.24M |
4 |
Jennison Associates
New York
|
-$2.55M |
5 |
SCM
Sio Capital Management
New York
|
-$1.56M |